COMP <GO>
NNNN vs IMDX // FORWARD P/E MULTIPLE
Anbio Biotechnology (Class A) (NASDAQ) VS. Insight Molecular Diagnostics Inc. (NASDAQ) • 15-METRIC TALLY: NNNN 7
— IMDX 2
■ METRIC PARITY
LAST: $3.72 (-3.12%) • MKT CAP: $535.3M
forward-pe
77.7x
LAST: $3.18 (0.00%) • MKT CAP: $104.1M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NNNN VS. IMDX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NNNN | IMDX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.20% | 56.70% | +30.50 | NNNN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.00% | -35.00% | +52.00 | NNNN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.26% | -24.38% | +23.12 | NNNN | /fcf-yield <GO> |
| Operating Margin | 66.70% | -60.00% | +126.70 | NNNN | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -1.20% | +69.20 | NNNN | /net-margins <GO> |
| Revenue Growth (YoY) | 5.60% | 115.60% | -110.00 | IMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | NNNN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.4 | 41.5 | -12.11 | IMDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 77.7x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $535.3M | $104.1M | $431.2M | NNNN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NNNN REV | IMDX REV | NNNN GROSS % | IMDX GROSS % | NNNN FCF | IMDX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.6M | $4.1M | 87.2% | 56.7% | -$6.7M | -$25.4M |
| FY 2024 | $8.2M | $1.9M | 71.9% | 39.3% | $2.1M | -$21.2M |
| FY 2023 | $6.7M | $1.5M | — | — | $898.4K | -$23.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NNNN // BETA —
IMDX // BETA —